|
|
|
|
| LEADER |
01373nam a2200217 u 4500 |
| 001 |
EB002000574 |
| 003 |
EBX01000000000000001163475 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Recommendations for drug therapies for relapsing-emitting multiple sclerosis
|h Elektronische Ressource
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c October 2013, 2013
|
| 300 |
|
|
|a 1 PDF file (ii, 19 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH therapeutic review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361342
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. For patients with relapsing-remitting multiple sclerosis (RRMS), what are the preferred initial pharmacological treatment strategies?2. For patients with RRMS, what are the pharmacological strategies for patients not adequately controlled on initial pharmacotherapy?3. Should combination strategies be considered for treatment of patients with RRMS? If so, what are the appropriate treatment options?
|